Catalog No.: PC-63177Not For Human Use, Lab Use Only.
TAK-828F (TAK-828) is a potent, selective, orally available RORγt inverse agonist with binding IC50 of 1.9 nM and reporter IC50 of 6.0 nM, displays excellent selectivity (>5,000-fold) against other ROR isoforms and nuclear receptors.
TAK-828F (TAK-828) is a potent, selective, orally available RORγt inverse agonist with binding IC50 of 1.9 nM and reporter IC50 of 6.0 nM, displays excellent selectivity (>5,000-fold) against other ROR isoforms and nuclear receptors.
TAK-828F shows robust and dose-dependent inhibition of IL-17A expression after oral administration at 0.3, 1 and 3 mg/kg bid in the mouse IL-23-induced cytokine expression model.
TAK-828F also demonstrates dose-dependent inhibition of RORγt regulated gene expression such as IL-17F, IL-22, and IL23 receptor, but no effect against IFN-γ expression.
TAK-828F significantly reduces the development of clinical symptoms in mouse experimental autoimmune encephalomyelitis model.
